GLSV invests in Santaris Pharma A/S
Global life science Ventures (GLSV) announced an investment in Santaris Pharma A/S in a Series B financing round totalling EUR40 million, as part of a syndicate led by ABN AMRO Capital Life Science and also including BankInvest, Novo Ventures, LD Pensions, Væksfonden, SPEF Ventures, InnovationsKapital and others. As part of the financing arrangement, Dr. Holger Reithinger from GLSV will join the Board of Directors of Santaris Pharma. Santaris Pharma, based in Hørsholm, Denmark, is a clinical stage biopharmaceutical company developing next generation RNA-silencing drugs for the treatment of cancer and metabolic diseases. The company, which was created in May 2003 through the merger of Cureon A/S and Pantheco A/S, owns the exclusive worldwide rights to the use of locked-nucleic acids (LNA) in pharmaceuticals . Santaris Pharma is using LNA to make novel, highly potent and stable RNA Antagonists. Such drugs have the potential to transform the field of RNA-targeted therapeutics, making specific and effective gene silencing a reality in human medicine. If this potential is realised, even in part, it should be possible to design new drugs to treat a wide variety of human diseases by switching off the Expression of harmful genes.
The proceeds of the financing will be used to bring the company's portfolio of RNA Antagonist drug candidates through early clinical safety and efficacy studies in oncology and metabolic disorders. The lead drug candidate, SPC 2996, is an RNA Antagonist of Bcl-2, a gene implicated in several cancers, and is currently in an international phase I/II clinical trial in chronic lymphocytic leukaemia. In addition, the funds will enable further development of Santaris Pharma's world leading platform for LNA-based therapeutics, including a recently announced program in LNA-based microRNA antagonists.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Photoswitchable Bactericide - Nanomaterial with “Light Switch” Kills Gram-negative or Gram-positive Bacteria
Carl Zeiss Meditec clearly on growth course
Kidney_dish

Origin.Bio secures $15 million funding to help manufacturers create a more sustainable future - Start-up connects bioengineers with nature to hack entirely new organisms, freeing manufacturers from petrochemical dependency

Useful “Fake” Peptides - Oligourea foldamers mimic peptides’ alpha-helices and effectively bind to drug targets
Category:Telerehabilitation
Integrated DNA Technologies expands global sales network - Company now selling directly to customers in South Korea
QIAGEN expands access to state-of-the-art HPV screening in China through co-marketing agreement with KingMed Diagnostics - Agreement will make HPV testing more widely available throughout China
